RENALYTIX PLC LS-0025
Research RENALYTIX PLC LS-0025 (2O9) on Bullrun: market cap EUR 20.54M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker2O9
- ExchangeF
- CountryUnited Kingdom
- SectorHealthcare
- IndustryHealth Information Services
- CurrencyEUR
- Market capEUR 20.54M
- Financial periodFY2025
- RevenueUSD 3.00M
- Revenue growth30.4%
- Net income-USD 20.40M
- Free cash flow-USD 17.90M
- Gross margin40.0%
Valuation Snapshot
latest market cap is EUR 20.54M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 3.00M | -USD 20.40M | -USD 17.90M | 40.0% | -0.07 | USD 3.60M | USD 8.30M | -USD 7.00M |
| FY2024 | USD 2.30M | -USD 45.50M | -USD 29.80M | 8.7% | -0.31 | USD 4.70M | USD 8.50M | -USD 9.00M |
| FY2023 | USD 3.40M | -USD 45.61M | -USD 34.09M | 21.2% | -0.56 | USD 24.68M | USD 12.12M | USD 6.97M |
| FY2022 | USD 2.97M | -USD 45.28M | -USD 46.59M | 29.4% | -0.82 | USD 41.33M | USD 12.34M | USD 30.61M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-27 | EUR 20.54M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 EUR.
About RENALYTIX PLC LS-0025
Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for clinical management of kidney diseases in Europe and the United States. It offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from electronic health record systems to generate a unique patient risk score.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is RENALYTIX PLC LS-0025's market cap?
RENALYTIX PLC LS-0025's market capitalization is EUR 20.54M.
What does RENALYTIX PLC LS-0025 do?
Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for clinical management of kidney diseases in Europe and the United States. It offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from electronic health record systems to generate a unique patient risk score.